News Headline Summary

EMA (European Medicines Agency) recommends Roche's (ROG) Perjeta for breast cancer

Reaction details (12:09)

- No immediate reaction to the news, last trade at CHF 186.40 (+0.27%)

14 Dec 2012 - 12:07 - Equities - Source: Newswires

Subscribe Now to RANsquawk

Click here for a 1 week free trial

RANsquawk provides audio news and commentary for over 15,000 professional traders and brokers worldwide. Services include: